Results 161 to 170 of about 1,129 (187)
Some of the next articles are maybe not open access.

DRUG UTILIZATION STUDY FOR AZILSARTAN MEDOXOMIL IN GERMANY

Journal of Hypertension, 2018
B. Ehlken   +4 more
openaire   +1 more source

Zero and first order derivative Ultraviolet Spectrophotometric Approach for Determining Azilsartan Medoxomil

Abstract: : Azilsartan medoxomil (AZIL), which is used to treat hypertension, reliably lowers blood pressure and is tolerable. By inhibiting the activity of the hormone angiotensin II at the AT1 receptor, which constricts blood vessels and limits water excretion through the kidneys, it decreases blood pressure. For the purpose of quantifying Azilsartan
Vasanth Kumar PM*, A Srinivasa Rao**
openaire   +1 more source

Achievement of Blood Pressure Targets and Safety of Azilsartan Medoxomil/Chlorthalidone Fixed Dose Combination versus Azilsartan Medoxomil in Hypertensive Patients Uncontrolled on Monotherapy

Journal of Hypertension, 2015
A. Juhasz   +7 more
openaire   +1 more source

Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention

Ca-A Cancer Journal for Clinicians, 2017
Cynthia Morata-Tarifa   +1 more
exaly  

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

Ca-A Cancer Journal for Clinicians, 2020
Aaron J Grossberg   +2 more
exaly  

Oral complications of cancer and cancer therapy

Ca-A Cancer Journal for Clinicians, 2012
Joel B Epstein   +2 more
exaly  

The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment

Ca-A Cancer Journal for Clinicians, 2018
Pricivel M Carrera   +2 more
exaly  

American Cancer Society Head and Neck Cancer Survivorship Care Guideline

Ca-A Cancer Journal for Clinicians, 2016
Nader Sadeghi   +2 more
exaly  

Spirituality and religion in oncology

Ca-A Cancer Journal for Clinicians, 2013
John R Peteet
exaly  

Home - About - Disclaimer - Privacy